Mass General Brigham Ventures — Full Portfolio
3 tracked investments · listed companies and verified rows first
Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor.
BiotechHealthtechNewton, US
John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Ryan Berry(Director)Donald McCarthy(Director)John Edwards(Director)Yajun Xu(Director)
BiotechBoston, US
David Allison(Director)Meredith Fisher(Director)Scott Rocklage(Executive Officer, Director)Roger Kitterman(Director)
Board seatMeredith FisherRoger Kitterman· per SEC Form D · $20M raise · filed Aug 2020
CodaMetrix builds AI-powered automation for medical coding within the healthcare revenue cycle, translating unstructured clinical data into reimbursement codes.
AI & Machine LearningDigital HealthHealthtechBoston, US
Hamid Tabatabaie(Director, Executive Officer, Promoter)Mark Pottle(Executive Officer)Tara Bradley(Executive Officer)Jim Whelan(Mr. Whelan is the Chief Revenue Officer of the Issuer.)Kevin Schmitt(Mr. Schmitt is the Chief Engineering Officer of the Issuer.)Jay Aslam(Mr. Aslam is the Chief Data Science Officer of the Issuer.)
Board seatRoger Kitterman· per SEC Form D · $15M raise · filed May 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.